Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.74 |
| ▸ | BCR | P11274 | 13/20 | 0.74 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 3/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397888 | 1.00 | ABL1 (0.74) | ABL1BCRNPY5RTP53GSK3B | |
| SCHEMBL18231590 | 0.89 | ABL1 (0.76) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL4098721 | 0.88 | NPY5R (0.57) | ABL1BCRNPY5RTP53GSK3B | |
| SCHEMBL16127577 | 0.88 | ABL1 (0.77) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3397763 | 0.86 | ABL1 (0.74) | ABL1BCRGSK3BKDM4EMAPT | |
| SCHEMBL3400278 | 0.86 | ABL1 (0.80) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL3397159 | 0.86 | ABL1 (1.00) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL29533256 | 0.84 | ABL1 (0.80) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL16363364 | 0.84 | ABL1 (0.80) | ABL1BCRKDM4EMAPTMAPK1 | |
| SCHEMBL4098855 | 0.83 | MAPT (0.53) | ABL1BCRNPY5RKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | claimed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | claimed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | claimed |
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1709007-A1 | N-4-(6-(HETEO)ARYL-PYRIMIDIN-4-YLAMINOPHENYL)-BENZENESULFONAMIDES AS KINASE INHIBITORS | Altana Pharma AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005070900-A1 | N-4-(6- (HETEO) ARYL-PYRIMIDIN-4-YLAMINOPHENYL) -BEZENESULFONAMIDES AS KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885NPY5R 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.